ContraFect Corp

NASDAQ:CFRX  
5.32
+0.04 (+0.76%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

CONTRAFECT Corp Stock, NASDAQ:CFRX

28 WELLS AVENUE, 3RD FLOOR, YONKERS, NY 10701
United States of America
Phone: 914-207-2300
Number of Employees: 20

Description

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.